Preclinical News and Research

RSS

Obesity suppresses natural protection against breast cancer growth

A research team at Huntsman Cancer Institute at the University of Utah (the U) has found that obesity prevents a biological process that kills cancerous cells, revealing a possible reason why obesity is a risk factor for breast cancer.

11 Sep 2026

Early studies hint that ketones may affect pathways linked to PTSD

An integrative review found that ketogenic therapy may influence metabolic, inflammatory, oxidative stress, and neurotransmitter pathways implicated in PTSD, with animal studies and small human studies reporting early signs of symptom improvement. Human evidence remains limited to very small cohorts, case reports, and pilot studies, and controlled trials have yet to establish clinical efficacy.

11 Sep 2026

Biolife granted U.S. patent for novel effervescent oral peptide delivery technology

BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease.

10 Sep 2026

Aging brain actively shapes biology and progression of tumors

Brain tumors develop within an organ that changes substantially with age. A new review in Ageing and Cancer Research & Treatment examines evidence that the aging brain microenvironment may influence brain tumor progression, treatment resistance, and cognitive outcomes.

10 Sep 2026

New funding supports LMU research on pediatric inflammatory bowel disease

The non-profit Boehringer Ingelheim Stiftung supports LMU clinician-scientist Daniel Kotlarz through its Rise up! program.

10 Sep 2026

Why researchers are looking at psilocybin for repeated mild head injuries

In female rats with repetitive mild head injury, psilocybin reduced acute imaging measures consistent with vasogenic edema and phosphorylated tau while altering vascular reactivity, functional connectivity, neurotrophic proteins, and lipid signaling. The findings provide preclinical evidence of potential therapeutic effects, but behavioral benefits were limited, and whether these biological changes translate into lasting neurological protection or benefits in humans remains unknown.

9 Sep 2026

Protein-based MRI agent detects tiny lung cancer metastases

A multi-institutional research team led by Georgia State University Regents' Professor Emerita of Biochemistry and Biophysical Chemistry Jenny J. Yang has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches.

9 Sep 2026

Study links methylglyoxal stress to immunotherapy resistance in triple-negative cancer

The metabolism of cancer cells may play a key role in their ability to evade the immune system. This is demonstrated by a new study conducted by researchers at the University of Liège, which reveals how methylglyoxal stress – a by-product of tumor metabolism – promotes immunosuppression and the formation of metastases, and may contribute to resistance to immunotherapy and the progression of triple-negative cancer.

9 Sep 2026

New blood screening algorithm reduces unnecessary Alzheimer's PET scans

A new blood-based screening algorithm dramatically reduced the number of unnecessary PET scans needed to recruit patients at risk of Alzheimer's disease for a clinical trial, according to research from scientists at the Keck School of Medicine of USC published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

9 Sep 2026

Fourier 80 Duo - Expanding access to NMR

Discover how the Fourier 80 Duo expands access to NMR with powerful benchtop performance, streamlined workflows, and expert insights from Bruker.

From Bruker BioSpin Group 9 Sep 2026

UCLA researchers develop scalable TCR therapy for solid tumors

T cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision. It's similar to another treatment, CAR T-cell therapy, but with one key difference: CAR T-cell therapy can only spot proteins that naturally appear outside of a cancer cell.

8 Sep 2026

New drug forces aggressive leukemia cells to die from stress

Pushing the accelerator and the brake at the same time is rarely a good idea. But researchers at the University of Gothenburg are using this approach to treat leukemia.

8 Sep 2026

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

A systematic review of 43 studies found highly heterogeneous results for GLP-1 receptor agonists across animal models and human research assessing depression-, anxiety-, and stress-related outcomes. No study directly tested these drugs as a treatment for PTSD, and the available evidence does not currently support their use for depression or PTSD, although people with metabolic dysfunction may warrant further investigation.

7 Sep 2026

Psilocybin microdosing sounds promising, but the strongest studies tell a different story

A systematic review of 11 studies involving 3,262 adults found that psilocybin mushroom and truffle microdosing was associated with reported improvements across areas including mental health, well-being, cognition, creativity, and social functioning. However, the evidence was methodologically weak and highly heterogeneous, the two placebo-controlled trials found no significant improvements, and inadequate adverse-event reporting means efficacy and safety remain uncertain.

7 Sep 2026

Inhibitory neurons act as a brake on brain tumor growth

Brain tumors do not grow in isolation. They develop within the highly active environment of the brain, where neurons continuously exchange electrical and chemical signals.

7 Sep 2026

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

7 Sep 2026

Psilocybin protects sensory nerves from chemotherapy damage in preclinical study

In mouse models, prophylactic psilocybin prevented or reduced multiple features of chemotherapy-induced peripheral neuropathy, with cycle-matched dosing sustaining protection during repeated cisplatin exposure without measurably affecting tumor growth. Experiments in human-derived sensory neurons and ex vivo peripheral nerves linked the effect to 5-HT2A-dependent preservation of mitochondrial trafficking and local axonal energy supply, while a nonhallucinogenic 5-HT2A agonist reproduced protection against mechanical hypersensitivity.

6 Sep 2026

What your gut microbes may have to do with how your brain ages

This review examines how diet-driven changes in the gut microbiota and microbial metabolites may influence cognitive aging through immune, metabolic, neural, endocrine, and barrier-related pathways. It highlights SCFAs, tryptophan-derived metabolites, and bile acids as key signaling mediators while emphasizing that much of the mechanistic evidence remains preclinical and human evidence is largely associative.

3 Sep 2026

The obesity-microbiome story is more complicated than ‘good’ and ‘bad’ bacteria

This review finds that obesity is linked to reciprocal interactions between diet, the gut microbiome, microbial metabolites, and host metabolic pathways that influence appetite, insulin sensitivity, inflammation, and energy balance across the lifespan. It highlights diet as a particularly tractable way to influence this system, while emphasizing that microbiome changes associated with GLP-1 therapies remain difficult to separate from weight loss and that functional multi-omics approaches may help enable more personalized interventions.

3 Sep 2026